

Ramón Reyes Bori

Presidente

Asociación Española Contra el Cáncer

Calle del Teniente Coronel Noreña 30
28045 Madrid

www.aelic.org

info@aelic.org

Paseo de la Habana 35,2D
28036 Madrid

Madrid, December 9, 2025

Subject: Letter from the Spanish Association of Patients with Cutaneous Lymphoma – AELIC regarding the call for proposals “AECC 70% Survival Challenge 2026”.

Dear AECC President,


The Spanish Association for Patients with Cutaneous Lymphoma is pleased to express its strong endorsement of the research initiative dedicated to advancing targeted immunotherapies for aggressive T-cell lymphomas, submitted under the AECC 70% Survival Challenge – 2026 Call, led by Drs. Sureda and Alarcón.

Aggressive T-cell lymphomas, both cutaneous and peripheral, remain among the most challenging hematological cancers, marked by limited therapeutic options and low survival rates. As an organization that works closely with patients and their families, we witness daily the profound impact of this reality. For this reason, we view this proposal as a highly meaningful and urgently needed contribution.

This project’s focus on next-generation immunotherapeutic strategies—including tumor-specific CAR-T approaches, bispecific antibodies, personalized vaccine platforms, and inhibitors directed at TCR-related pathways—aligns with the unmet need for treatments that are both more effective and less harmful. We particularly appreciate that the research aims not only to destroy malignant T cells but also to safeguard immune function, an aspect of critical importance for patient well-being and long-term prognosis. Our association places great value on integrating patient perspectives throughout the research process. We are fully prepared to collaborate with the consortium, especially in the areas of patient engagement, dissemination, and awareness activities, to ensure that the project remains aligned with the lived experiences and priorities of those affected.

We are confident that the outcomes of this initiative will meaningfully advance the care and survival of individuals living with T-cell lymphomas. For these reasons, we are proud to offer our full support.

Sincerely,



Almudena Montejo Pérez

President

Spanish Association of Patients with Cutaneous Lymphoma - AELIC

Madrid, June 12, 2025

To whom it may concern,

On behalf of AEAL, the Spanish Association of Patients Affected by Lymphoma, Myeloma and Leukemia, we would like to express our full support for the research proposal led by Professor José Ramón Regueiro, focused on developing targeted immunotherapies for aggressive T-cell lymphomas, within the framework of the AECC 70% Survival Challenge – 2026 Call.


As a patient organization, we are deeply aware of the urgent need for more effective and less toxic treatments for aggressive T-cell lymphomas, which currently present very low survival rates and limited therapeutic options. We believe this project, based on innovative strategies such as tumor-specific CAR-T therapies, bispecific antibodies, personalized vaccines and TCR-pathway inhibitors, addresses a major unmet medical need.

We particularly value the project's commitment to preserving immune function while eliminating malignant T cells, a crucial aspect for maintaining quality of life and long-term survival in patients.

AEAL strongly supports the inclusion of patient perspectives in all stages of research and is fully committed to collaborating with the consortium throughout the development of the project, especially in areas related to patient involvement, dissemination, and awareness-raising.

We are confident that this initiative will contribute significantly to improving outcomes and survival for patients with T-cell lymphomas and are proud to lend our support.

Sincerely,



President

AEAL, Asociación Española de Afectados por Linfoma, Mieloma y Leucemia



CUTANEOUS LYMPHOMA FOUNDATION

Letter of Support for TCR-directed therapies for aggressive T-cell lymphomas

Team Coordinators

Anna Sureda

Balbino Alarcón

Lead Institutions

ICO-IDIBELL

CSIC-CBMSO

Province

Barcelona

Madrid

To Whom It May Concern,

On behalf of the Cutaneous Lymphoma Foundation, we are writing to express our enthusiastic support for the proposed research project being led by Drs Anna Sureda and Balbino Alarcón in Spain. As a global patient organization dedicated to serving individuals affected by cutaneous lymphoma, we understand the critical need for innovative research that advances knowledge and improves outcomes for patients living with this rare and often misunderstood disease.

This project, which seeks to include a combination of extensive epidemiological, clinical and molecular characterization of T-cell lymphomas to train AI to generate a better classification tool predictive of disease progression and sensitivity to targeted therapies. The AI tool will help to identify patient-specific TCR signaling knots, define prognostic indices of patient evolution, and recommend aggressive vs non-aggressive therapies and represents an important step toward closing significant gaps in both clinical understanding and the diagnostic challenges. Particularly in rare diseases, where data is often limited and patient experiences underrepresented, efforts like this are invaluable to the international community.

Furthermore, we support the multi-center approach that incorporates centers across Spain in order to bring together the expertise as well as represent the geographical regions. Additional benefits of this research is the inclusion of young scientists who will be introduced to this rare field of lymphoma, supporting the continuation of young clinicians and researchers in the field.

Our organization is committed to amplifying the voice of patients and families around the world. We strongly believe that this study aligns with that mission and are confident that the results of this work will contribute meaningfully to the global body of knowledge, foster greater collaboration, and ultimately, help to improve the lives of those affected.

PO Box 969, Warren, MI 48090 Phone: (248) 644-9014
info@clfoundation.org www.clfoundation.org



CUTANEOUS LYMPHOMA FOUNDATION

We are proud to offer our full support and look forward to following the progress of this important research. Please do not hesitate to contact us if we can be of any further assistance.

With sincere appreciation,

Susan Thornton

CEO, Cutaneous Lymphoma Foundation

4th June 2025

To Whom It May Concern,

I am writing to express my strong support for the research project entitled **TCR-directed therapies for aggressive T-cell lymphomas**, led by Dr. Anna Sureda at ICO-IDIBELL and Dr. Balbino Alarcón at CSIC-CBMSU, and Dr Pablo L Ortiz Romero, Hospital 12 de Octubre]and their teams.

This initiative directly addresses a critical unmet need in the care of patients with aggressive primary cutaneous T-cell lymphomas (CTCLs)—a rare and often devastating subset of non-Hodgkin lymphomas.

While many patients with early-stage CTCL can experience prolonged survival and quality of life, those with aggressive variants—including advanced-stage mycosis fungoides, Sézary syndrome, and other rare phenotypes such as gamma-delta or CD8+ cytotoxic lymphomas—face a disproportionately poor prognosis. Despite their urgency, these cases remain underrepresented in clinical research, leading to limited therapeutic options and non-standardized approaches to diagnosis and treatment.

The proposed project is timely and innovative. It aims to [brief summary of research goals—e.g., identify biomarkers, evaluate novel therapies, integrate genomic profiling with clinical data, develop risk stratification tools, etc.], and will have a direct impact on patient care through the development of more precise and effective treatment pathways. Importantly, the project aligns with our international cutaneous lymphoma mission to advance the understanding and treatment of cutaneous lymphomas worldwide, with a particular focus on aggressive subtypes where international collaboration is most urgently needed.

The multidisciplinary nature of this proposal and the commitment to collaboration across institutions and borders is strongly encouraged. The cutaneous lymphoma community stands ready to support efforts that can ultimately improve survival and quality of life for patients facing the most challenging forms of this disease.

I fully endorse this project and urge funding agencies and academic bodies to give it their highest consideration.

Please do not hesitate to contact me if further information or could be of assistance.

Yours Faithfully,

Prof Julia Scarisbrick MBChB FRCP MD
Consultant Dermatologist, University Hospital Birmingham, UK
International Society of Cutaneous Lymphoma (ISCL) President